Selected article for: "enhanced expression and SARS cov"
Author: Lijiao Zeng; Jialu Li; Mingfeng Liao; Rui Hua; Pilai Huang; Mingxia Zhang; Youlong Zhang; Qinlang Shi; Zhaohua Xia; Xinzhong Ning; Dandan Liu; Jiu Mo; Ziyuan Zhou; Zigang Li; Yu Fu; Yuhui Liao; Jing Yuan; Lifei Wang; Qing He; Lei Liu; Kun Qiao
Title: Risk assessment of progression to severe conditions for patients with COVID-19 pneumonia: a single-center retrospective study
  • Document date: 2020_3_30
    • ID: 8n3q30hy_32
    Snippet: SARS-CoV-2 entry host cell through angiotensin-converting enzyme 2 (ACE2) 7 , whose expression can be enhanced by the usage of hypertension medicine such as ACE inhibitors or angiotensin II type-I receptor blockers (ARBs) 8 . Whether such medication is a causal factor for a higher risk of COVID-19 progression is thus under investigation 9 . In our study, we observed that the co-occurred hypertension disorder is significantly related to severe pro.....
    Document: SARS-CoV-2 entry host cell through angiotensin-converting enzyme 2 (ACE2) 7 , whose expression can be enhanced by the usage of hypertension medicine such as ACE inhibitors or angiotensin II type-I receptor blockers (ARBs) 8 . Whether such medication is a causal factor for a higher risk of COVID-19 progression is thus under investigation 9 . In our study, we observed that the co-occurred hypertension disorder is significantly related to severe progression, but we did not found association between the medication and severity outcome among hypertension patients. All rights reserved. No reuse allowed without permission. author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

    Search related documents:
    Co phrase search for related documents
    • ACE inhibitor and angiotensin II type ACE inhibitor: 1, 2, 3, 4
    • ACE inhibitor and arb receptor blocker: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
    • ACE inhibitor and entry host: 1, 2, 3, 4
    • ACE inhibitor and entry host cell: 1, 2
    • ACE inhibitor and high risk: 1, 2, 3, 4
    • ACE inhibitor and hypertension patient: 1
    • ACE inhibitor and receptor blocker: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29
    • ACE inhibitor and severity medication: 1
    • angiotensin convert and entry host: 1
    • angiotensin convert and hypertension patient: 1
    • angiotensin convert enzyme and entry host: 1
    • angiotensin II type ACE inhibitor and arb receptor blocker: 1
    • angiotensin II type ACE inhibitor and entry host: 1
    • angiotensin II type ACE inhibitor and receptor blocker: 1, 2
    • angiotensin II type and arb receptor blocker: 1, 2
    • angiotensin II type and entry host: 1, 2, 3
    • angiotensin II type and high risk: 1, 2
    • angiotensin II type and receptor blocker: 1, 2, 3, 4, 5, 6, 7
    • arb receptor blocker and high risk: 1, 2